Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Head and neck cancers

4533 - Concurrent cisplatin and Dose escalation with Intensity-modulated radiotherapy (IMRT) versus conventional chemo-radiotherapy for locally advanced (LA) head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial


20 Oct 2018


Poster Discussion session - Head and neck cancers


Cytotoxic Therapy;  Radiation Oncology

Tumour Site

Head and Neck Cancers


Yungan Tao


Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287


Y. Tao1, A. Auperin2, P. Blanchard3, M. Alfonsi4, X. Sun5, M. Rives6, Y. Pointreau7, J. Castelli8, P. Graff6, S. Wong Hee Kam9, J. Thariat10, O. Veresezan11, A. Cornely12, O. Casiraghi13, M. Lapeyre14, J. Bourhis15

Author affiliations

  • 1 Radiation oncology, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 2 Biostatistics, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 3 Radiation oncology, Gustave Roussy - Cancer Campus, 98500 - Villejuif/FR
  • 4 Radiotherapy, Clinique Sainte Catherine, avignon/FR
  • 5 Radiotherapy, Hopital Nord Franche-Comté de Montbéliard & CHRU de Besançon, Montbéliard/FR
  • 6 Radiotherapy, Institut Claudius Régaud, Toulouse/FR
  • 7 Radiotherapy, Centre Jean Bernard, Le Mans/FR
  • 8 Radiotherapy, Centre Eugène Marquis, Rennes/FR
  • 9 Radiotherapy, AP-HM Hôpital de la Timone, Marseille/FR
  • 10 Radiation oncology, Centre François Baclesse, Caen/FR
  • 11 Radiotherapy, Centre Henri Becquerel, Rouen/FR
  • 12 Radiation oncology, Gustave Roussy - Cancer Campus, Villejuif/FR
  • 13 Biopathology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 14 Radiotherapy, Centre Jean Perrin, Clermont-Ferrand/FR
  • 15 Radiation oncology, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4533


IMRT is currently routine practice for HNSCC due to its ability to decrease toxicities as compared to conventional 3DRT. For the first time we reported randomized data (Bourhis, ASCO 2017) showing that dose escalation with IMRT could still maintain lower toxicity in the context of concurrent chemo-radiotherapy (CRT). Indeed, despite a higher total dose delivered with IMRT, side effects were lower as compared to 3DRT. We present updated results of this randomized trial integrating p16 and smoking information.


patients were randomized between 70 Gy/35F in 7 weeks with conventional RT (arm A) versus 75 Gy/35F with IMRT (arm B). A sequential boost of 2.5Gy × 10 after 50Gy/25F was given to initial tumor volume in arm B. In both arms, patients (pts) received 3 cycles of cisplatin at 100 mg/m2 during RT. To detect a hazard ratio (HR) of 0.56 in LRC, inclusion of 310 pts was required to observe 109 loco-regional progressions and achieve 85% power at 2-sided significance level of 0.05.


Between 2005 and 2015, 188 pts were randomized (closed prematurely because of slow accrual): 82% were males, median age 58 years, 85% had oropharynx and 73% stage IVa. The initial characteristics were well balanced between arms. P16 status was known for 137 (86%) of 160 oropharyngeal cancers with p16+ in 53 (39%), 90% were > 10 pack-year smokers. The median follow-up was 60 months. Acute and late xerostomia were markedly improved in IMRT arm. The 1-year grade 0-1 salivary toxicity (RTOG) was 34% vs 81% (p < 0.0001) in arm A and B respectively. However, the increase of dose with IMRT did not transfer in a higher LRC probability with an adjusted HR of 1.15 [0.66-2.00] (p = 0.62). PFS, overall survival (OS) were not significantly different between the 2 arms. Better LRC, PFS or OS were found in p16+ than in p16- cancers and no interaction were observed between p16 and treatment arms.


Dose escalation with IMRT did not improve LRC in LA-HNSCC patients treated with concomitant CRT, regardless of p16 status. This trial adds to the body of evidence to support the use of IMRT in LA-HNSCC.

Clinical trial identification


Legal entity responsible for the study



Has not received any funding.

Editorial Acknowledgement


J. Bourhis: Consulting or advisory role: Merck Serono, MSD Oncology, AstraZeneca, BMS. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.